Ncats-DPI-22-0101 - creation of an open-source process to manufacture AAV vector-based gene therapy candidates for non-commercial clinical studies
Active Awarded Last action
- Contract number
- 75N91022F00016
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $13,973,744
Award facts
- Contract value 100% obligated
- $13,973,744.00 Current and potential, with all options
- Completion date 59% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $2,437,886 | |
| Terminate for Convenience | -$220,697 | |
| Terminate for Convenience | $0 | |
| Change Order | $2,448,234 | |
| Original award | $9,308,321 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 12, 2022, with a ceiling value of $13.97 million, for creation of an open-source process to manufacture AAV vector-based gene therapy candidates for non-commercial clinical studies under the NCATS-DPI-22-0101 program.
Place of performance is Frederick, Maryland. The order is cost-plus-fixed-fee and carries an ultimate completion date of September 11, 2029.
Service Contract Inventory reporting shows this order's actual government-invoiced labor activity: FY2023 recorded $29 thousand across 0.1 FTEs and 286 contractor hours at $102.68/hr; FY2024 invoiced $702 thousand across 4.6 FTEs and 9,495 contractor hours at $73.89/hr; FY2025 invoiced $458 thousand across 1.7 FTEs and 3,456 contractor hours at $132.61/hr. The derived blended government-paid hourly rate rose year-over-year from FY2024 to FY2025. In FY2025, Leidos Biomedical Research engaged one subcontractor for 91 percent of contractor hours on this order.
Quick answers
Who was awarded contract 75N91022F00016?
75N91022F00016 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 12, 2022.
How much is contract 75N91022F00016 worth?
The government has obligated $13,973,744 on 75N91022F00016.
Is contract 75N91022F00016 an order under another contract?
Yes. 75N91022F00016 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00016 competed?
The extent of competition for 75N91022F00016 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award